Jasper Therapeutics(US:JSPR) Globenewswire·2025-10-10 19:38Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1] Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lead plaintiff must file a motion with the court by November 18, 2025, to represent other class members [3] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] - The firm has achieved significant settlements in the past, including the largest securities class action settlement against a Chinese company at the time [4] - Rosen Law Firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4] Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with regulations [5] - It is claimed that these failures increased the risk of negative outcomes in clinical trials and overstated the company's financial and business prospects [5] - The lawsuit asserts that when the true details became known, investors suffered damages due to the misleading public statements [5]